Questions? Feedback? powered by Olark live chat software

EGF

Cancer metabolism is often times exploited and used for cancer treatments. The metabolism of cancer is often thought of as cancer’s weak spot. The metabolism of cancer is an extremely rapid, non-discriminative replicating process. This is what allows for it to take over and starve surrounding tissues of their nutrients. Typically, cells will use fuel within itself to carry out the cellular processes for which that cell is created. In cancer, this fuel is used specifically to replicate rather than carry out any other tasks. New aged cancer treatments are targeting metabolic reprogramming in an attempt to control the rate at which cancer can reproduce. Cancer growth factors are polypeptides that stimulate cell proliferation. They are major regulatory proteins controlling cell growth. The growth factors are rate limiting, meaning when their supplies are exhausted, growth comes to a halt or slows drastically. There are many types of growth factors like EGFs, FGFs, hormones, insulin and insulin-like, PDGFs, TGFs, TNFs, and VEGFs. EGF stands for epidermal growth factor. The epidermal growth factor binds to the epidermal growth factor receptor on the cell surface. EGF stimulates cell growth, proliferation, and differentiation. It is 53 amino acids in length and has three disulfide bonds. Epidermal growth factor is present in human platelets, macrophages, urine, saliva, milk, and plasma. It has a very high affinity to bind to its matching receptor which stimulates the protein-kinase activity of the receptor. This, in turn, activates a signal transduction pathway that can cause calcium levels inside of the cell to rise, glycolysis to increase, or protein synthesis to commence. EGF inhibition by way of monoclonal EGF antibodies has been shown to decrease cancer risk.

Anti-Polycystin 1 antibody binds against the target polycystin 1. Polycystin 1 is an ion-channel regulator and is involved in protein to protein and protein to carbohydrate adhesion. Defects in PKD1 are the cause of polycystic kidney disease. Polycystic kidney disease is a genetic disorder in which affected individuals may form cysts on their kidneys, causing them to grow in size. Typically, PKD follows a dominant inheritance, but there is also a recessive form caused by mutations in polycystin 1. The autosomal recessive form is much rarer, and typically appears in infancy. Anti-EPS8 antibody binds against the target epidermal growth factor receptor kinase substrate 8. EPS8 is expressed in many different tissues like heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas. Upon EPS8 binding to an EGF receptor, it enhances the epidermal growth factor dependent mitogenic signals. EPS8 can bind to multiple targets.

 
Product Number Title Applications Host Clonality
AC21-0427-01 Anti-EPS8 Antibody (AMCA) ELISA, IHC Goat Polyclonal
AC21-0427-02 Anti-EPS8 Antibody (AP) ELISA, IHC Goat Polyclonal
AC21-0427-03 Anti-EPS8 Antibody (APC) ELISA, IHC Goat Polyclonal
AC21-0427-04 Anti-EPS8 Antibody (APC-Cy5.5) ELISA, IHC Goat Polyclonal
AC21-0427-05 Anti-EPS8 Antibody (APC-Cy7) ELISA, IHC Goat Polyclonal
AC21-0427-06 Anti-EPS8 Antibody (Avidin) ELISA, IHC Goat Polyclonal
AC21-0427-07 Anti-EPS8 Antibody (Biotin) ELISA, IHC Goat Polyclonal
AC21-0427-08 Anti-EPS8 Antibody (BPE) ELISA, IHC Goat Polyclonal
AC21-0427-09 Anti-EPS8 Antibody (Cy3) ELISA, IHC Goat Polyclonal
AC21-0427-10 Anti-EPS8 Antibody (Cy5) ELISA, IHC Goat Polyclonal
AC21-0427-11 Anti-EPS8 Antibody (Cy5.5) ELISA, IHC Goat Polyclonal
AC21-0427-12 Anti-EPS8 Antibody (FITC) ELISA, IHC Goat Polyclonal